Briefing
FDA expands blinatumomab (Blincyto) approval to MRD-positive B-cell precursor ALL
On March 29, 2018, FDA granted accelerated approval of blinatumomab for adults and children with B-cell precursor ALL in first or second complete remission with MRD ≥0.1%, based on the single-arm BLAST study. Supporting trial results are in Gökbuget et al., Blood 2018 (PMID 29358182).
- Design: regulatory
- Assay: MRD ≥10^-3 (0.1%) as the eligibility threshold in BLAST